Brief: Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming The Potential Of ALK's House Dust Mite Tablet In Young Children

Alk-Abello A/S

08/06/2023 16:39

June 8 (Reuters) - ALK-Abello A/S  ALKb.CO :
    * LARGE PHASE 3 CLINICAL TRIAL SUCCESSFULLY MEETS PRIMARY
ENDPOINT, CONFIRMING THE POTENTIAL OF ALK’S HOUSE DUST MITE
TABLET IN YOUNG CHILDREN
    * ALK-ABELLO A/S - PRIMARY AND ALL KEY SECONDARY
CONFIRMATORY
ENDPOINTS WERE MET
    * ALK-ABELLO A/S - RESULTS WERE HIGHLY STATISTICALLY
SIGNIFICANT
AND CONSISTENT ACROSS MULTIPLE ENDPOINTS
    * ALK-ABELLO A/S - SUBJECT TO APPROVAL, HDM TABLET COULD BE
AVAILABLE FOR YOUNG CHILDREN IN EUROPE AND NORTH AMERICA IN
2024/25

Source text for Eikon:  ID:nGNX1hJXRy 
Further company coverage:  ALKb.CO 

 ((Reuters.Briefs@thomsonreuters.com;))